OncoMatch/Clinical Trials/NCT05277688
Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients
Is NCT05277688 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies adjuvant concurrent chemoradiotherapy for cervical cancer.
Treatment: adjuvant concurrent chemoradiotherapy — To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Disease stage
Required: Stage IA2, IB, IIA, IIB
Demographics
Prior therapy
Must have received: radical hysterectomy — adjuvant
Accepted radical hysterectomy 3-4 weeks before
Cannot have received: chemotherapy
no previous chemotherapy
Cannot have received: radiotherapy
no previous...radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05277688 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IA2 or IB or IIA or IIB is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages